18 completed, 8 terminated, 5 withdrawn, 3 active not recruiting. 19 Phase 1, 16 Phase 2, 5 Phase 3.
Follow parsaclisib: new trials by email Literature Review of parsaclisib trials Research Report on parsaclisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia Parsaclisib - Autoimmune Hemolytic Anemia | Not yet recruiting | Peking Union Medical College Hospital | 22 | 2025-09-01 | 2025-09-02 | |
| Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma lenalidomide, rituximab, parsaclisib - Follicular Lymphoma | Phase 1 | Withdrawn | Innovent Biologics (Suzhou) Co. Ltd. | 2023-07-28 | 2023-10-17 | |
| To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) parsaclisib, rituximab, obinutuzumab - Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) | Phase 3 | Withdrawn | Incyte Corporation | 2022-12-30 | 2022-07-18 | |
| Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia parsaclisinib, placebo - Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase 3 | Terminated | Incyte Corporation | 13 | 2022-03-15 | 2025-11-03 |
| A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma parsaclisib, rituximab, bendamustine - Mantle Cell Lymphoma | Phase 3 | Withdrawn | Incyte Corporation | 2022-03-11 | 2022-04-29 | |
| Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL Parsaclisib, CHOP - PI3Kδ Inhibitor, Parsaclisib | Phase 1 / Phase 2 | Unknown | Fudan University | 30 | 2022-03-01 | 2022-02-14 |
| PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Parsaclisib, Chidamide - Peripheral T-Cell Lymphoma | Phase 1 | Terminated | Henan Cancer Hospital | 12 | 2022-02-20 | 2025-12-02 |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) tafasitamab, parsaclisib - Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 54 | 2021-09-16 | 2026-02-04 |
| Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas Parsaclisib, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Walter Hanel | 5 | 2021-09-01 | 2025-01-17 |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 177 | 2021-05-26 | 2025-10-02 |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 252 | 2021-05-24 | 2025-10-21 |
| To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment. parsaclisib - Advanced Malignancies | Phase 1 | Completed | Incyte Corporation | 48 | 2021-05-04 | 2022-08-17 |
| To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment. parsaclisib - Advanced Malignancies | Phase 1 | Completed | Incyte Corporation | 21 | 2021-03-29 | 2022-08-26 |
| To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) tafasitamab, lenalidomide, parsaclisib - Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Incyte Biosciences Japan GK | 72 | 2020-12-15 | 2026-10-21 |
| Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) parsaclisib - Lymphoma | Phase 2 | Completed | Incyte Biosciences Japan GK | 42 | 2020-09-30 | 2024-10-23 |
| Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib - B-Cell Malignancies | Phase 2 | Active not recruiting | Incyte Corporation | 112 | 2020-08-03 | 2026-06-25 |
| Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib - Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma | Phase 1 | Active not recruiting | Mayo Clinic | 50 | 2020-06-15 | 2026-02-02 |
| Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer Parsaclisib - Breast Cancer, Breast Neoplasms | Phase 1 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2020-06-01 | 2020-11-03 | |
| IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma IBI376 - Indolent Non-hodgkin Lymphoma | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 81 | 2020-04-07 | 2024-06-05 |
| A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris Parsaclisib - Pemphigus Vulgaris | Phase 2 | Withdrawn | Incyte Corporation | 2019-03-01 | 2019-09-13 |
Showing 20 of 36. Sign in to see all of them.
Lymphoma, Follicular (8) · Lymphoma, Non-Hodgkin (8) · Lymphoma (7) · Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Mantle-Cell (4) · Myeloproliferative Disorders (4) · Recurrence (4) · Hereditary Sensory and Autonomic Neuropathies (3) · Primary Myelofibrosis (3) · Anemia, Hemolytic, Autoimmune (2) · Breast Neoplasms (2) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1)
Incyte Corporation (26) · Incyte Biosciences Japan GK (2) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Fudan University (1) · Henan Cancer Hospital (1) · Mayo Clinic (1) · Peking Union Medical College Hospital (1) · UNC Lineberger Comprehensive Cancer Center (1) · Walter Hanel (1)
United States (24) · Italy (12) · Spain (11) · France (9) · Belgium (8) · Poland (8) · United Kingdom (8) · Germany (7) · Israel (7) · Japan (7) · Austria (6) · Denmark (6) · Czechia (5) · China (4) · Hungary (4)
Kathleen Butler, MD (4) · Fred Zheng, MD (3) · Albert Assad, M.D (1) · Albert Assad, M.D. (1) · Albert Assad, MD (1) · Carey Lisa, MD (1) · Cinthya Coronado, MD (1) · Claudia Corrado, M.D. (1) · Claudia Corrado, MD (1) · Ekaterine Asatiani, M.D. (1) · Fitzroy Dawkins, MD (1) · Fred Zheng, MD, PhD (1) · Junning Cao (1) · Lance Leopold, MD (1)
PMID 30803990, PMID 33140664, PMID 35288468, PMID 38115208, PMID 38290135, PMID 38598516, PMID 39435908, PMID 40365847, PMID 41563911, PMID 42827632
2017 (5), 2016 (2), 2019 (1)